Johns Hopkins Bloomberg School of Public HealthCAAT

CAAT Advisory Board (US and Europe)

The CAAT Advisory Board was established in 1981 to provide oversight and direction to CAAT staff. Representing industry, academia, the U.S. and European regulatory communities, and the animal welfare community, its members meet annually to review recent progress and discuss future initiatives. Once every three years, the Advisory Board gathers at a board retreat to map long-range plans for the Center. In addition, CAAT board members from academic institutions are responsible for reviewing applications submitted annually to the CAAT grant program and selecting recipients.

CAAT always welcomes new organizations to the board. Please contact us if you are interested in details. (caat@jhsph.edu).

(Updated October 18, 2012)

CAAT US Board

  • Melvin E. Andersen, (The Hamner Institute for Health Science)
  • Rebecca Bascom, (Penn State University)
  • Heidi Bialk (Pepsi Co)
  • Kim Boekelheide (Brown University)
  • Rodger Curren (Institute for In Vitro Sciences)
  • David Dix (US Enoironmental Protection Agency)
  • Suzanne C. Fitzpatrick, (US Food and Drug Administration)
  • James J. Freeman, (ExxonMobil Biomedical Sciences, Inc.)
  • Anthony A. Gaspari, (University of Maryland)
  • Alan M. Goldberg, (Johns Hopkins University)
  • Thomas Hartung (Johns Hopkins University)
  • A. Wallace Hayes, (Harvard School of Public Health)
  • Michael P. Holsapple (Battelle)
  • Eric Hutchinson (Johns Hopkins Medical Institutions)
  • David Jacobson-Kram (US Food & Drug Administration)
  • Ann Jernigan (Pfizer Inc.)
  • Randy King, (The Procter and Gamble Company)
  • Herman B.W.M. Koëter, (Orange House Partnership)
  • Daniel Krewski, (University of Ottawa)
  • Elizabeth Marincola (Society for Science & the Public)
  • Monicah Otieno, (Johnson & Johnson)
  • Bernard Robaire, (McGill University)
  • Noel R. Rose, (Johns Hopkins University)
  • Andrew N. Rowan, (Humane Society of the United States)
  • Markus Schmutz (Novartis)
  • Thomas Singer (F. Hoffmann-La Roche Ltd.)
  • Nigel Skinner (Agilent)
  • David Steup (Shell Oil Company)
  • William Stokes (National Institute of Environmental Health Sciences)
  • Gihan I. Tennekoon, (University of Pennsylvania)
  • Eve Lloyd Thompson (Bernice Barbour Foundation, Inc.)
  • Horst Wenck (Beiersdorf AG)
  • Carl Westmoreland (Unilever)
  • David Wilcox (Research Institute for Fragrance Materials, Inc.)
  • James D. Yager, (Johns Hopkins University)

CAAT-Europe Board

  • Nathalie Alepee (L’Oréal)
  • Sonja von Aulock (ALTEX)
  • Bas J. Blaauboer (Utrecht University)
  • Alexander Bürkle (University of Konstanz)
  • Mardas Daneshian (CAAT-Europe)
  • Ulrich Deschl (Boehringer-Ingelheim Pharma GmbH & Co. KG)
  • Daniel R. Dietrich (University of Konstanz)
  • Michelle Embry (ILSI Health and Enviornmental Sciences Institute, HESI)
  • Alan M. Goldberg (Johns Hopkins University)
  • Franz P. Gruber (Doerenkamp-Zbinden Foundation)
  • Thomas Hartung (Johns Hopkins University)
  • Joanna Jaworska (Procter and Gamble, Eurocor)
  • Lisbeth Knudsen (ECOPA)
  • Harald Krug (Empa—Swiss Federal Laboratories for Materials Science & Technology)
  • Marcel Leist (University of Konstanz)
  • Frauke Ohl (University if Utrecht)
  • Walter Pfaller (Innsbruck Medical University)
  • Donald Prater (FDA Europe Office)
  • Bennard van Ravenzwaay and Tzutzuy Ramirez-Hernandez (BASF)
  • Kirsty Reid (Eurogroup for Animals/EWLA)
  • Wolfram Riedel (BSL Bioservice Scientific Laboratories GmbH)
  • Markus Schmutz (Novartis)
  • Michael Schwarz (University of Tübingen)
  • Troy Seidle (Humane Society International)
  • Andrea Seiler (Zebet)
  • Thomas Singer (F. Hoffmann-La Roche, Ltd.)
  • Nigel Skinner (Agilent Technologies)
  • Horst Wenck and Andreas Schepky (Beiersdorf AG)
interest